title: Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin.
authors.forename: A P
authors.initials: AP
authors.lastname: Barreiros
authors.forename: J F
authors.initials: JF
authors.lastname: Schlaak
authors.forename: G
authors.initials: G
authors.lastname: Gerken
authors.forename: P R
authors.initials: PR
authors.lastname: Galle
authors.forename: H F
authors.initials: HF
authors.lastname: Löhr
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D019233:Retreatment; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018712:Analgesics, Non-Narcotic; D000998:Antiviral Agents; D007376:Interleukin-2; D012254:Ribavirin